Bank of America Issues Pessimistic Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective trimmed by Bank of America from $575.00 to $547.00 in a research note issued to investors on Thursday morning,Benzinga reports. The brokerage currently has an underperform rating on the biopharmaceutical company’s stock.

Other equities analysts have also recently issued research reports about the company. UBS Group cut Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the company from $1,130.00 to $738.00 in a report on Thursday, January 16th. Sanford C. Bernstein decreased their price objective on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. Truist Financial dropped their target price on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. Leerink Partnrs raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th. Finally, Robert W. Baird dropped their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a research note on Wednesday, February 5th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, eighteen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $963.56.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $563.16 on Thursday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The firm has a fifty day moving average of $647.99 and a 200 day moving average of $743.86. The firm has a market cap of $61.57 billion, a PE ratio of 14.71, a PEG ratio of 2.34 and a beta of 0.44. Regeneron Pharmaceuticals has a one year low of $525.99 and a one year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter in the previous year, the company earned $11.86 earnings per share. The company’s quarterly revenue was up 10.3% on a year-over-year basis. As a group, research analysts predict that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were issued a $0.88 dividend. The ex-dividend date was Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.63%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 2.30%.

Institutional Trading of Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Pinney & Scofield Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $25,000. Rakuten Securities Inc. increased its stake in Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 15 shares during the period. OFI Invest Asset Management acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $28,000. Avalon Trust Co purchased a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $36,000. Finally, Crowley Wealth Management Inc. acquired a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $36,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.